OBJECTIVE: Autoantibodies to citrullinated proteins are specific for rheumatoid arthritis (RA) and recognize epitopes centered by citrulline, a posttranslationally modified form of arginine. Peptidyl arginine deiminase type 4 (PAD-4), the enzyme that converts arginine into citrulline, is in itself a target for RA-specific autoantibodies. This study was undertaken to assess whether anti-PAD-4 autoantibodies interfere with citrullination in vitro in patients with RA, and to identify peptide targets of anti-PAD-4 antibodies that can activate or inhibit citrullination. METHODS: To test whether autoantibodies to PAD-4 influence citrullination, an in-house citrullination assay was developed using purified autoantibodies to PAD-4. To map B cell epitopes on PAD-4, 65 overlapping 20-mer peptides encompassing the entire PAD-4 were analyzed for their reactivity in RA sera. RESULTS: Autoantibodies to PAD-4 inhibited PAD-4-mediated citrullination. Three linear peptides on PAD-4 were recognized almost uniquely by PAD-4 autoantibodies in the sera of patients with RA. One peptide was located in the N-terminal, calcium-binding domain of PAD-4, while 2 other peptides were located in the C-terminal, substrate-binding domain of PAD-4. CONCLUSION: Autoantibodies to PAD-4 inhibit in vitro citrullination of fibrinogen by PAD-4. Most anti-PAD-4-positive sera recognize peptides located both in the N-terminal domain (211-290) and the C-terminal domain (601-650) of PAD-4.
OBJECTIVE: Autoantibodies to citrullinated proteins are specific for rheumatoid arthritis (RA) and recognize epitopes centered by citrulline, a posttranslationally modified form of arginine. Peptidyl arginine deiminase type 4 (PAD-4), the enzyme that converts arginine into citrulline, is in itself a target for RA-specific autoantibodies. This study was undertaken to assess whether anti-PAD-4 autoantibodies interfere with citrullination in vitro in patients with RA, and to identify peptide targets of anti-PAD-4 antibodies that can activate or inhibit citrullination. METHODS: To test whether autoantibodies to PAD-4 influence citrullination, an in-house citrullination assay was developed using purified autoantibodies to PAD-4. To map B cell epitopes on PAD-4, 65 overlapping 20-mer peptides encompassing the entire PAD-4 were analyzed for their reactivity in RA sera. RESULTS: Autoantibodies to PAD-4 inhibited PAD-4-mediated citrullination. Three linear peptides on PAD-4 were recognized almost uniquely by PAD-4 autoantibodies in the sera of patients with RA. One peptide was located in the N-terminal, calcium-binding domain of PAD-4, while 2 other peptides were located in the C-terminal, substrate-binding domain of PAD-4. CONCLUSION: Autoantibodies to PAD-4 inhibit in vitro citrullination of fibrinogen by PAD-4. Most anti-PAD-4-positive sera recognize peptides located both in the N-terminal domain (211-290) and the C-terminal domain (601-650) of PAD-4.
Authors: Z Reyes-Castillo; C A Palafox-Sánchez; I Parra-Rojas; G E Martínez-Bonilla; S del Toro-Arreola; M G Ramírez-Dueñas; G Ocampo-Bermudes; José F Muñoz-Valle Journal: Clin Exp Immunol Date: 2015-09-16 Impact factor: 4.330
Authors: Elizabeth D Ferucci; Erika Darrah; Irene Smolik; Tammy L Choromanski; David B Robinson; Marianna M Newkirk; Marvin J Fritzler; Antony Rosen; Hani S El-Gabalawy Journal: J Rheumatol Date: 2013-08-01 Impact factor: 4.666
Authors: Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin I O'Donnell; William R Gilliland; Jess D Edison; Antony Rosen; Erika Darrah; Jill M Norris; V Michael Holers Journal: Arthritis Rheum Date: 2010-09
Authors: Erika Darrah; Jon T Giles; Michelle L Ols; Herbert G Bull; Felipe Andrade; Antony Rosen Journal: Sci Transl Med Date: 2013-05-22 Impact factor: 17.956
Authors: M Kristen Demoruelle; Hong Wang; Ryan L Davis; Ashley Visser; Johnny Hoang; Jill M Norris; V Michael Holers; Kevin D Deane; Erika Darrah Journal: Arthritis Res Ther Date: 2021-06-06 Impact factor: 5.156